Form 4: NEUROONE Director Sells Shares Under 10b5-1 Plan

NEUROONE Medical Technologies' Business Development Director, Mark Christianson, sold 13,720 shares of common stock in two transactions.

Summary

• Mark Christianson, Business Development Director at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), disposed of 13,720 shares of common stock.
• The sales occurred on March 10, 2026, and March 11, 2026, under a pre-arranged Rule 10b5-1(c) trading plan.
• On March 10, 2026, 11,611 shares were sold at a weighted average price of $0.80 per share, with prices ranging from $0.80 to $0.8102.
• On March 11, 2026, an additional 2,109 shares were sold at a weighted average price of $0.80 per share, with prices ranging from $0.80 to $0.805.
• Following these transactions, Mark Christianson beneficially owns 215,200 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sale was pre-planned under a 10b5-1, an insider reducing their stake, particularly at a relatively low share price, can suggest a lack of strong conviction in near-term price appreciation or a need for personal liquidity.

Negatives

• An insider, the Business Development Director, reduced their stake in the company by selling 13,720 shares.
• The sales occurred at a relatively low price point of $0.80 per share.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even under a pre-arranged 10b5-1 plan, can sometimes be interpreted by the market as a signal of an insider's view on the company's future prospects or a need for personal liquidity. In the medical technology sector, such sales are routinely monitored for insights into management's confidence.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a common practice across industries, including medical technology, allowing insiders to diversify holdings or manage liquidity without concerns about trading on material non-public information.
• The volume of shares sold (13,720) represents a relatively small percentage of the director's total holdings (approximately 6% of the remaining 215,200 shares), which is not uncommon for routine portfolio management compared to more significant divestitures seen in other companies like a CEO selling a substantial portion of their stake in a tech giant such as Apple or Microsoft.

Stakeholder Impact

• Shareholders may interpret the insider sale as a potential lack of confidence from a key executive, which could influence investor sentiment.
• The sale, while pre-planned, reduces the alignment of the Business Development Director's personal wealth with the company's stock performance.

Key Dates

Recommendation

While insider selling can be a negative signal, the presence of a 10b5-1 plan mitigates the immediate bearish interpretation, suggesting a pre-planned diversification or liquidity event rather than a reaction to adverse news. The volume sold is also not a complete divestiture. Investors should hold and monitor future insider activity and company performance for clearer directional signals.

Keywords

NEUROONE Medical Technologies, NMTC, Insider Sale, Form 4, Stock Transaction, Officer Sale, 10b5-1 Plan